Curzio Rüegg
CEO
Xemperia
Fribourg, Switzerland
I am professor of pathology at University of Fribourg and cofounder of Xemperia SA. My research focuses on the role of immune cells in breast cancer metastasis.
My organisation
About me
Curzio Rüegg, MD, trained in immunology, cell and molecular biology. From 1993 to 2010 he was in Lausanne as head of research at CHUV/UNIL, ISREC affiliate and member of the NCCR Molecular Oncology program. Since 2010 he is Full Professor of Pathology at University of Fribourg and rotating department Chair. From 2014 to 2020 he was co-director of the NCCR program in bio-inspired materials. He authored over 180 papers and gave over 200 lectures worldwide. His research focuses on tumor microenvironment, metastasis and biomarkers in breast cancer. He is member of national and international scientific committees, advisory boards and the Senate of the Swiss Academy of Medical Sciences. He co-founded Novigenix and Xemperia active in cancer diagnostics. Xemperia will bring the next generation of cancer detection tests to the market. He holds numerous patents.
My organisation
XEMPERIA, founded in 2023 as a spin-off from the University of Fribourg, Switzerland, leverages over 25 years of pioneering expertise in translational cancer research and biomarker discovery.
Our vision is to lead the development of innovative blood tests for cancer detection and monitoring, empowering doctors to make informed therapeutic decisions.
Our mission is to reduce cancer mortality and improve patients' quality of life by enabling the earliest possible detection and treatment of cancer.
At XEMPERIA, we harness the body's natural responses to cancer, identifying cancer-associated biomarkers in the blood through cutting-edge multiomics methodologies.
Our flagship project focuses on a blood test for the early detection of breast cancer, utilizing the immune system's response to the disease. This test has successfully completed an initial phase of clinical validation, and we are now preparing for a large-scale validation study, aiming for certification and commercialization by 2028.
Simultaneously, XEMPERIA is advancing DNA-based nanosensors for detecting RNA/DNA, offering rapid, sensitive, and cost-effective cancer detection. Initially developed for research purposes, these tests have the potential for future clinical applications.
Speaker sessions (1)
Tuesday, 10 December 2024
10:15 - 11:20
Pitch Sessions Healthtech
Experience the forefront of healthtech innovation at EPFL Investor Day!